WS #15210
The biotech sector showed divergent performance: Regeneron was upgraded to Buy by Argus, citing strong pipeline value, while Anixa Biosciences advanced its CAR-T therapy for ovarian cancer. Conversely, Foghorn Therapeutics ended development of its lead asset FHD-909, shifting focus to its internal pipeline. This mix highlights the high-risk, high-reward nature of the sector, where clinical milestones drive significant volatility.
Biotech Clinical & Corporate
The biotech sector showed divergent performance: Regeneron was upgraded to Buy by Argus, citing strong pipeline value, while Anixa Biosciences advanced its CAR-T therapy for ovarian cancer. Conversely, Foghorn Therapeutics ended development of its lead asset FHD-909, shifting focus to its internal pipeline. This mix highlights the high-risk, high-reward nature of the sector, where clinical milestones drive significant volatility.